Current drug development portfolio for antimalarial therapies.
In response to the emergence of parasite drug resistance to currently deployed antimalarials, the scientific community, in partnership with the pharmaceutical industry and public organizations, has fashioned an antimalarial drug development portfolio for the sustained development and registration of safe, effective and cheap antimalarial medicines. The management of this portfolio is being driven by MMV (Medicines for Malaria Venture), with a number of projects recently reaching the clinical end of this drug development pipeline.
Biagini
Giancarlo A
GA
Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK. biagini@liverpool.ac.uk
O'Neill
Paul M
PM
Bray
Patrick G
PG
Ward
Stephen A
SA
D000962:Antimalarials / Q000737:chemistry* / Q000191:economics / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015195:Drug Design; D006801:Humans; D008288:Malaria / Q000188:drug therapy*; D015394:Molecular Structure; D035703:Therapies, Investigational
D000962:Antimalarials